Ra Pharmaceuticals (RARX) reports Q4 loss per share of 47c, announces significant progress on its first XR formulation of zilucoplan

(Updated - March 7, 2019 7:39 AM EST)

Ra Pharmaceuticals (NASDAQ: RARX) reported Q4 EPS of ($0.47), $0.20 better than last year.

Ra Pharma today announced significant progress on its first XR formulation of zilucoplan, with a single subcutaneous dose resulting in rapid attainment of target drug concentrations for greater than one week in non-human primates, supporting once weekly or less frequent dosing. Of note, near complete inhibition of terminal complement activity for greater than one week was achieved without the need for prior intravenous loading doses, as measured by an ex vivo hemolysis assay. Data from the XR development program will be presented at the 6th Annual Peptides Congress, April 24-25, 2019, in London, UK. Ra Pharma continues to evaluate the pharmacokinetic profiles of this and other formulations to optimize the XR dosing regimen. Ra Pharma anticipates the XR program entering human clinical studies in the first half of 2020

For earnings history and earnings-related data on Ra Pharmaceuticals (RARX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• StablecoinX reports Q2 2026 results with $34.2M net loss